FIELD: biotechnology.
SUBSTANCE: invention relates to a site-specific mono-pegylated analog of the exendin, and can be used in medicine. The use of the more stable protecting group Dde (N-1-α(4,4-dimethyl-2,6-dioxo-cyclohexylene)) at the stage of synthesis of the exendin analog allows avoiding the side effects of polypegylation of the protein not prevented by unstable protecting groups.
EFFECT: invention makes it possible to achieve a high yield of a mono-pegylated analog of the exendin at a low reaction molar ratio compared to known methods for the preparation of derivatives of this kind.
11 cl, 6 dwg, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MULTI-RECEPTOR AGONIST AND MEDICAL USE THEREOF | 2020 |
|
RU2816492C2 |
| NEW COMPOSITIONS OF EXENDINE AGONISTS AND METHODS OF THEIR ADMINISTRATION | 2000 |
|
RU2242244C2 |
| MODIFIED ANALOGUES OF GIP PEPTIDE | 2019 |
|
RU2817673C2 |
| DERIVATIVE OF INSULINOTROPIC PEPTIDE THAT CONTAINS MODIFIED N-ENDED AMINOACID | 2008 |
|
RU2442792C2 |
| ENGINEERED BOTULINUM NEUROTOXIN | 2016 |
|
RU2746736C2 |
| METHODS FOR DELIVERY OF NEUROPROTECTIVE POLYPEPTIDE TO CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2790566C2 |
| SWINE G-CSF VARIANTS AND APPLICATION THEREOF | 2018 |
|
RU2823074C2 |
| GLP-1 PEPTIDE HAVING ATTACHED OLIGOSACCHARIDE CHAIN | 2008 |
|
RU2539829C2 |
| GIP AGONIST COMPOUNDS AND METHODS | 2015 |
|
RU2716985C2 |
| COMPOSITE POLYPEPTIDE HAVING METAL-BINDING MOTIF AND MOLECULAR STRUCTURE CONTAINING THEREOF | 2020 |
|
RU2814475C2 |
